MX2010014044A - Peptidos de epitope cdca1 y vacunas que contienen los mismos. - Google Patents
Peptidos de epitope cdca1 y vacunas que contienen los mismos.Info
- Publication number
- MX2010014044A MX2010014044A MX2010014044A MX2010014044A MX2010014044A MX 2010014044 A MX2010014044 A MX 2010014044A MX 2010014044 A MX2010014044 A MX 2010014044A MX 2010014044 A MX2010014044 A MX 2010014044A MX 2010014044 A MX2010014044 A MX 2010014044A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- antigen
- polypeptides
- methods
- cdca1
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 101150033450 NUF2 gene Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 101000590482 Homo sapiens Kinetochore protein Nuf2 Proteins 0.000 abstract 3
- 102100032431 Kinetochore protein Nuf2 Human genes 0.000 abstract 3
- 210000001808 exosome Anatomy 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 3
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen vacunas de péptido contra cáncer. En particular, la presente invención describe péptidos de epítope derivados de CDCA1 que provocan CTLs. La presente invención también proporciona CTLs establecidas que reconocen específicamente células objetivo positivas HLA-A24 pulsadas con los péptidos. También se proporcionan células que presentan antígenos y exomas que presentan cualesquiera de los péptidos, así como métodos para inducir las células que presentan antígeno. La presente invención proporciona además agentes farmacéuticos que contienen los polipéptidos CDCA1 o polinucleótidos que codifican los mismos, así como exomas y células que presentan antígeno como ingredientes activos. Además, la presente invención- proporciona métodos para tratar y/o para la profilaxis de (por ejemplo, evitar) cánceres (tumores) y/o prevención de recurrencia postoperatoria de los mismos, así como a métodos para inducir CTLs, métodos para inducir inmunidad anti-tumor, utilizando los polipéptidos CDCA1, polinucleótidos que codifican los polipéptidos, exornas de células que presentan antígenos que presentan los polipéptidos, o los agentes farmacéuticos de la presente invención. Los cánceres que serán dirigidos incluyen, pero no se limitan a, cáncer de seno, cáncer de vejiga, cáncer de esófago, cáncer de pulmón de célula pequeña (SCLC) y cáncer de pulmón de célula no pequeña (NSCLC).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7406208P | 2008-06-19 | 2008-06-19 | |
| US19759908P | 2008-10-28 | 2008-10-28 | |
| PCT/JP2009/002771 WO2009153992A1 (en) | 2008-06-19 | 2009-06-18 | Cdca1 epitope peptides and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010014044A true MX2010014044A (es) | 2011-03-03 |
Family
ID=41433910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010014044A MX2010014044A (es) | 2008-06-19 | 2009-06-18 | Peptidos de epitope cdca1 y vacunas que contienen los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9387238B2 (es) |
| EP (1) | EP2303912B1 (es) |
| JP (1) | JP5640262B2 (es) |
| KR (2) | KR101705011B1 (es) |
| CN (1) | CN102119171B (es) |
| AU (1) | AU2009261382B2 (es) |
| BR (1) | BRPI0914782B1 (es) |
| CA (1) | CA2728268C (es) |
| DK (1) | DK2303912T3 (es) |
| ES (1) | ES2658842T3 (es) |
| IL (1) | IL209967A (es) |
| MX (1) | MX2010014044A (es) |
| RU (1) | RU2502740C2 (es) |
| SG (1) | SG191680A1 (es) |
| TW (1) | TWI526219B (es) |
| WO (1) | WO2009153992A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298933A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| PT2186889E (pt) | 2007-08-20 | 2015-06-17 | Oncotherapy Science Inc | Péptido cdca1 e agente farmacêutico que o compreende |
| TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP2776451B1 (en) * | 2011-11-11 | 2018-07-18 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| WO2013133405A1 (ja) | 2012-03-09 | 2013-09-12 | オンコセラピー・サイエンス株式会社 | ペプチドを含む医薬組成物 |
| JP6255593B2 (ja) | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン |
| LT3456339T (lt) | 2013-08-05 | 2021-12-10 | Immatics Biotechnologies Gmbh | Nauja imunoterapija nuo kelių navikų, tokių kaip plaučių vėžys, įskaitant nlpv |
| TWI777195B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三） |
| US10676514B2 (en) * | 2014-08-04 | 2020-06-09 | Oncotherapy Science, Inc. | CDCA1-derived peptide and vaccine containing same |
| EP3207936B1 (en) * | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| TW202023581A (zh) | 2018-08-02 | 2020-07-01 | 日商腫瘤療法 科學股份有限公司 | 來自cdca1的胜肽及含有此的疫苗 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69635895D1 (de) | 1995-08-03 | 2006-05-04 | Rijksuniversiteit Te Leiden Le | Antigen presentierende bläschen, die von zellen ableiten |
| EP0983357A1 (en) | 1997-05-23 | 2000-03-08 | Biogen, Inc. | Modulators of tissue regeneration |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| KR100653590B1 (ko) | 1998-06-25 | 2006-12-04 | 교고 이또 | 시클로필린 ｂ 유래의 종양 항원 펩티드 |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US20030170255A1 (en) | 1999-06-30 | 2003-09-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6858204B2 (en) | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AU769143B2 (en) | 1999-06-30 | 2004-01-15 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20020172952A1 (en) | 1999-06-30 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AU7721500A (en) | 1999-09-29 | 2001-04-30 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US6432966B2 (en) | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU2002218770A1 (en) | 2000-07-11 | 2002-01-21 | Corixa Corporaton | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| AU2002327945A1 (en) | 2001-09-17 | 2003-04-01 | Eirx Therapeutics Limited | Human delta-n p73 molecules and uses thereof |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| WO2003105891A2 (en) | 2002-06-12 | 2003-12-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
| EP2261247A3 (en) | 2002-09-12 | 2011-02-16 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
| CN101113478A (zh) | 2002-09-30 | 2008-01-30 | 肿瘤疗法科学股份有限公司 | 诊断睾丸精原细胞瘤的方法 |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| EP1556490A4 (en) * | 2002-10-22 | 2006-04-05 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| CA2507924A1 (en) | 2002-12-10 | 2004-07-01 | Endocube Sas | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
| TW200512298A (en) | 2003-09-24 | 2005-04-01 | Oncotherapy Science Inc | Method of diagnosing breast cancer |
| TW200533376A (en) | 2004-03-24 | 2005-10-16 | Oncotherapy Science Inc | Compositions and methods for treating lung cancer |
| EP1856278A2 (en) | 2005-02-10 | 2007-11-21 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EP2295570A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| EP2298933A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| US7943295B2 (en) | 2005-07-29 | 2011-05-17 | Oncotherapy Science, Inc. | Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex |
| US7776341B2 (en) | 2006-08-10 | 2010-08-17 | Colorado State University Research Foundation | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens |
| EP2192179B9 (en) | 2007-08-20 | 2017-11-15 | Oncotherapy Science, Inc. | Cdh3 peptide and medicinal agent comprising the same |
| PT2186889E (pt) | 2007-08-20 | 2015-06-17 | Oncotherapy Science Inc | Péptido cdca1 e agente farmacêutico que o compreende |
| TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
| JP6255593B2 (ja) * | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン |
-
2009
- 2009-06-17 TW TW098120220A patent/TWI526219B/zh active
- 2009-06-18 EP EP09766440.3A patent/EP2303912B1/en active Active
- 2009-06-18 KR KR1020117000740A patent/KR101705011B1/ko active IP Right Grant
- 2009-06-18 KR KR1020167027024A patent/KR20160119264A/ko not_active Application Discontinuation
- 2009-06-18 BR BRPI0914782-9A patent/BRPI0914782B1/pt active IP Right Grant
- 2009-06-18 MX MX2010014044A patent/MX2010014044A/es active IP Right Grant
- 2009-06-18 WO PCT/JP2009/002771 patent/WO2009153992A1/en active Application Filing
- 2009-06-18 RU RU2011101709/10A patent/RU2502740C2/ru active
- 2009-06-18 DK DK09766440.3T patent/DK2303912T3/en active
- 2009-06-18 JP JP2010549745A patent/JP5640262B2/ja active Active
- 2009-06-18 CN CN200980131202.7A patent/CN102119171B/zh active Active
- 2009-06-18 CA CA2728268A patent/CA2728268C/en active Active
- 2009-06-18 US US12/999,051 patent/US9387238B2/en active Active
- 2009-06-18 SG SG2013046503A patent/SG191680A1/en unknown
- 2009-06-18 ES ES09766440.3T patent/ES2658842T3/es active Active
- 2009-06-18 AU AU2009261382A patent/AU2009261382B2/en active Active
-
2010
- 2010-12-13 IL IL209967A patent/IL209967A/en active IP Right Grant
-
2016
- 2016-06-08 US US15/176,444 patent/US10711047B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0914782A2 (pt) | 2016-07-26 |
| EP2303912A1 (en) | 2011-04-06 |
| TWI526219B (zh) | 2016-03-21 |
| EP2303912A4 (en) | 2012-08-29 |
| JP5640262B2 (ja) | 2014-12-17 |
| US9387238B2 (en) | 2016-07-12 |
| ES2658842T3 (es) | 2018-03-12 |
| CN102119171A (zh) | 2011-07-06 |
| DK2303912T3 (en) | 2018-03-12 |
| AU2009261382A1 (en) | 2009-12-23 |
| TW201000120A (en) | 2010-01-01 |
| US20110189214A1 (en) | 2011-08-04 |
| CA2728268C (en) | 2017-11-07 |
| KR20110031314A (ko) | 2011-03-25 |
| RU2011101709A (ru) | 2012-07-27 |
| WO2009153992A1 (en) | 2009-12-23 |
| EP2303912B1 (en) | 2018-01-03 |
| CN102119171B (zh) | 2014-08-06 |
| BRPI0914782B1 (pt) | 2021-08-31 |
| KR20160119264A (ko) | 2016-10-12 |
| KR101705011B1 (ko) | 2017-02-23 |
| US20160272692A1 (en) | 2016-09-22 |
| RU2502740C2 (ru) | 2013-12-27 |
| JP2011524737A (ja) | 2011-09-08 |
| IL209967A0 (en) | 2011-02-28 |
| IL209967A (en) | 2015-09-24 |
| SG191680A1 (en) | 2013-07-31 |
| AU2009261382B2 (en) | 2013-08-15 |
| CA2728268A1 (en) | 2009-12-23 |
| US10711047B2 (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MA39907A (fr) | Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MX2015012012A (es) | Peptidos de kntc2 y vacunas que los contienen. | |
| GB201004575D0 (en) | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers | |
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| EA202091233A3 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
| WO2016145234A3 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
| MX2014001675A (es) | Peptidos de mphosph1 y vacunas que incluyen los mismos. | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| RU2022100330A (ru) | Пептид, полученный из depdc1, и содержащая его вакцина | |
| SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| SG10201900879PA (en) | Cdca1-derived peptide and vaccine containing same | |
| BR112013005448A2 (pt) | peptídeos de ttll4 e vacinas contendo os mesmos. | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| MX2019013163A (es) | Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma). | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
| MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |